跳至主要内容
临床试验/NCT04184232
NCT04184232已完成2 期

Treatment of Recurrent Bladder Cancer With Autologous Monocyte-derived Dendritic Cells

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus1 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2019年7月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
17
试验地点
1
主要终点
Efficacy evaluation

研究概览

简要总结

Treatment of recurrent bladder cancer with dendritic cells

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
Male
接受健康志愿者
否

入选标准

  • •Histologically confirmed diagnosis of pTa bladder cancer;
  • •Patient who require repetitive transurethral resection;
  • •Expression of muc-1/wt-1 by the tumor;
  • •EGOC 0-3;

排除标准

  • •any medical condition which can be associated with the high risk for the patient;
  • •pregnancy/lactation;
  • •chronic infections, including hepatitis B/C, tuberculosis, HIV

研究组 & 干预措施

Dendritic cells

Experimental

Patients with the recurrent bladder cancer receiving standard treatment and autologous dendritic cells

干预措施: Dendritic cells (Biological)

Dendritic cells

Experimental

Patients with the recurrent bladder cancer receiving standard treatment and autologous dendritic cells

干预措施: Standard treatment according to the Clinical protocols (Other)

Control

Active Comparator

Patients with the recurrent bladder cancer receiving standard treatment

干预措施: Standard treatment according to the Clinical protocols (Other)

结局指标

主要结局

Efficacy evaluation

时间窗: 1 year

1 year relapse free survival

次要结局

未报告次要终点

研究者

研究点 (1)

Loading locations...

相似试验

Treatment of Recurrent Bladder Cancer With Dendritic... | 临床试验